RxDoctor Payments Data

Judy Risch

Optometrist · Richmond, INNPI 1568449155

Payments from drug & device makers

$1,476in general payments, 2019–2025

Across 67 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$698
  • Sun Pharmaceutical Industries Inc.$120
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$113
  • Glaukos Corporation$89
  • Novartis$84
  • Bausch & Lomb Americas Inc.$82
  • plus $290 from 14 others

What the payments were for

  • Food & beverage$1,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,476 in reported general payments places this provider in the 70th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$142,542
Medicare patients
565
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost278$127,480
XiidraLifitegrast81$70,863
RestasisCyclosporine61$62,407
Alphagan PBrimonidine Tartrate112$44,436
SimbrinzaBrinzolamide/Brimonidine Tart96$28,971
RocklatanNetarsudil Mesylat/Latanoprost61$25,783
CombiganBrimonidine Tartrate/Timolol48$16,419
Betaxolol Hcl159$15,828
RhopressaNetarsudil Mesylate23$12,737
VyzultaLatanoprostene Bunod22$10,718
Travoprost74$9,689
Fluorometholone90$5,668
Latanoprost272$3,141
Dorzolamide Hcl147$2,924
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat149$2,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$698$250,742499 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$82$81,582103 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$17$38,52084 claims
AlconSimbrinza$59$28,97196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →